

# Clinical Features Of 2019-nCoV

Dr. M.Javanian M.D Babol University of Medical Sciences

#### Clinical characteristics of 2019 novel coronavirus infection in China

Wei-jie Guan, Zheng-yi Ni, Yu Hu, Wen-hua Liang, Chun-quan Ou, Jian-xing He, Lei Liu, Hong Shan, Chun-liang Lei, David SC Hui, Bin Du, Lan-juan Li, Guang Zeng, Kowk-Yung Yuen, Ru-chong Chen, Chun-li Tang, Tao Wang, Ping-yan Chen, Jie Xiang, Shi-yue Li, Jin-lin Wang, Zi-jing Liang, Yi-xiang Peng, Li Wei, Yong Liu, Yahua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Nan-shan Zhong

Methods: We extracted the data on <u>1,099 patients</u> with laboratory-confirmed 2019-nCoV ARD from <u>552 hospitals</u> in <u>31 provinces/provincial</u> municipalities through January 29th, 2020

Results: The median age was 47.0 years, and 41.90% were females. Only 1.18% of patients had a direct contact with wildlife, whereas 31.30% had been to Wuhan and 71.80% had contacted with people from Wuhan

0.9% of patients were aged below 15 years

Fever (87.9%) and cough (67.7%) were the most common symptoms

Diarrhea is uncommon

This study has shown that <u>fever occurred in only</u>

43.8% of patients with 2019-nCoV ARD <u>on</u>

presentation but <u>developed in 87.9% following</u>

hospitalization

The median incubation period was 3.0 days (range, 0 to 24.0 days)

On admission, ground-glass opacity was the typical radiological finding on chest computed tomography (50.00%)

Lymphopenia was observed in 82.1% of patients


55 patients (5.00%) were admitted to intensive care unit and 15 (1.36%) succumbed.

The percentages of patients being admitted to the ICU, requiring invasive ventilation and death were 5.00%, 2.18% and 1.36%, respectively

➤ Pneumonia was not mandatory for inclusion. 20.9% patients have isolated 2019–nCoV infection before or without the development of viral pneumonia.


>However, based on a larger sample size and cases recruited throughout China, we found a markedly **lower case fatality rate (1.4%)** as compared with that reportedly recently [1,12]. The fatality rate was lower (0.88%) when incorporating additional pilot data from Guangdong province (N=603) where effective prevention has been undertaken (unpublished data). Our findings were consistent with the national official statistics, reporting the mortality of 2.01% in China out of 28,018 cases as of February 6th, 2020


Case 1





Case 2






Case 3

3A First chest CT

3B Second chest CT



سرفه، تب، ناتوانی سردرد شروع ناگهانی ترشحات بینی و التهاب حلق درد عضلاني، التهاب ملتحمه گلودرد درد زیر جناغ سینه سرفه همراه با خلط 0% <1. <7. <7. <4. <6. <7. <7. <1.


- On January 19, 2020, a 35-year-old man presented to an urgent care clinic in Snohomish County, Washington, with a 4-day history of cough and subjective fever.
- He disclosed that he had returned to Washington State on January 15 after traveling to visit family in Wuhan, China

- The physical examination revealed a body temperature of 37.2°C,
- blood pressure of 134/87 mm Hg,
- pulse of 110 beats per minute,
- respiratory rate of 16 breaths per minute, and oxygen saturation of 96% while the patient was breathing ambient air
- Chest X-ray was normal

- NAAT was negative for all pathogen tested.
- On January 20, 2020, the CDC confirmed that the patient's nasopharyngeal and oropharyngeal swabs tested positive for 2019-nCoV by real-time reversetranscriptase-polymerase-chain-reaction (rRT-PCR) assay

- On hospital day 6 (illness day 10), a fourth chest radiograph showed basilar streaky opacities in both lungs, a finding consistent with atypical pneumonia, and rales were noted in both lungs on auscultation.
- Treatment with intravenous <u>remdesivir</u> (a novel nucleotide analogue prodrug in development) was initiated on the evening of day 7, and no adverse events were observed in association with the infusion

- On hospital day 8 (illness day 12), the patient's clinical condition improved.
- Supplemental oxygen was discontinued, and his oxygen saturation values improved to 94 to 96% while he was breathing ambient air.




A 33-year-old otherwise healthy German businessman (Patient 1) became ill with a sore throat, chills, and myalgias on January 24, 2020. The following day, a fever of 39.1°C (102.4°F) developed, along with a productive cough. By the evening of the next day, he started feeling better and went back to work on January 27

- Before the onset of symptoms, he had attended meetings with a Chinese business partner at his company near Munich on January 20 and 21.
- The business partner, a Shanghai resident, had visited Germany between Jan. 19 and 22. During her stay, she had been well with no signs or symptoms of infection but had become ill on her flight back to China, where she tested positive for 2019–nCoV on January 26

On January 27, she informed the company about her illness. Contact tracing was started, and the above-mentioned colleague was sent to the Division of Infectious Diseases and Tropical Medicine in Munich for further assessment

- At presentation, he was afebrile and well. He reported no previous or chronic illnesses and had no history of foreign travel within 14 days before the onset of symptoms.
- Two nasopharyngeal swabs and one sputum sample were obtained and were found to be positive for 2019-nCoV on quantitative reverse-transcriptase-polymerase-chain-reaction

On January 28, three additional employees at the company tested positive for 2019-nCoV (Patients 2 through 4 in Fig. 1). Of these patients, only Patient 2 had contact with the index patient; the other two patients had contact only with Patient 1.



### تعریف موارد بیماري براي نظام مراقبت

مورد مشكوك (مورد مشكوك موردي است كه بايد نمونه گيري شده و بررسي هاي بيشتري درمورد آن انجام پذيرد) فرد مبتلا به پنوموني (بيماري شديد تنفسي تب دار) سرفه و تنگي نفس نيازمند بستري در بيمارستان مي باشد، و يک عامل بيماريزاي ديگري براي توجيه علائم بيماري وي متصور نيست. كه حداقل يكي از مشخصات ذيل را دارا باشد:

الف- سابقه سفر به کشور چین، در عرض ۱۶ روز قبل از شروع علائم بیماري بب- علي رغم درمان هاي مناسب براي پنوموني، پاسخ بالیني نامناسب بوده و به شکل غیرمعمول و غیرقابل انتظاري وضعیت بالیني بیمار حادتر و وخیم تر شود (بدون توجه به سابقه سفر و ملیت بیمار و با تایید فوکال پوینت دانشگاه).

بيمار داراي علائم تنفسي (با هر شدتي كه باشد)، كه در عرض ١٤ روز قبل از شروع علائم باليني يكي از انواع تماس هاي ذيل را داشته باشد:

الف- تماس نزدیك (Close Physical Contact)با مورد قطعي و علامتدار بیماري ۱۹-۲۰۱۹

ب- مراقبت مستقیم از بیمار مبتلا به SARIناشی از ۲۰۱۹-nCoV محتمل/ قطعی)

تبصره: پزشكان در مورد تظاهرات غيرتنفسي و غيرمعمول بيماري در افراد با نقص ايمنى بايد هوشيار باشند

## از توجه شما سیاسگزارم